Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that new therapies with novel mechanisms of action from Servier/Novartis, Sanofi-Aventis, and NeuroSearch/GlaxoSmithKline will achieve more than $4 billion in sales in the major depressive disorder drug market.

The new Pharmacor report entitled Major Depressive Disorder finds that the launches of Servier/Novartis's agomelatine, Sanofi-Aventis's saredutant and amibegron and NeuroSearch/GlaxoSmithKline's GSK-372475 will garner 50% patient share by 2016, following their launches beginning in 2009. The report also finds that some atypical antipsychotics, including AstraZeneca's Seroquel XR and Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify, are seeking approval or have attained approval for treatment-resistant depression and will reach their peak sales as a class for this indication before 2016. Patient share for this drug class will continue to grow between 2011 and 2016, but generic erosion will constrain sales to just under $1.5 billion in 2016.

According to the report, the generic erosion of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) will cause sales in the overall major depressive disorder drug market to remain static between 2006 and 2016.

"Antidepressants with completely novel mechanisms of action hold the promise of treating the many patients who respond inadequately to SSRIs and/or SNRIs," said Carlos Dedesma, Ph.D., analyst at Decision Resources. "These novel agents also lack the sexual dysfunction side effects that plague SSRIs - - thus, they are poised to command premium pricing."

About Major Depressive Disorder

Major depressive disorder is a debilitating psychiatric illness associated with significant costs. It is characterized by one or more major depressive episodes without a history of manic or hypomanic episodes. The number of people suffering from major depressive disorder will increase from approximately 42 million in 2006 to nearly 44 million in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Although numerous branded and generic agents are available to treat depression, several unmet needs leave significant opportunity for drug developers.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Antibiotics from Theravance/Astellas and Johnson & Johnson/Basilea Are the Most Promising in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drug Market

View Now